Hydrocortisone dosing during puberty in patients with classical congenital adrenal hyperplasia: An evidence-based recommendation

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 10, 2009, Pages 3882-3888

  Bonfig, Walter ^a   Pozza, Susanne Bechtold Dalla ^a   Schmidt, Heinrich ^a   Pagel, Philipp ^b   Knorr, Dietrich ^a   Schwarz, Hans Peter ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCORTISONE;

ADRENARCHE; ARTICLE; BODY HEIGHT; BODY MASS; BREAST DEVELOPMENT; CHILD; CONGENITAL ADRENAL HYPERPLASIA; CORTICOSTEROID THERAPY; DRUG EFFECT; FEMALE; GROWTH RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENARCHE; PRIORITY JOURNAL; PUBERTY; RETROSPECTIVE STUDY; SALT WASTING; SHORT STATURE; STATISTICAL ANALYSIS; TESTIS DEVELOPMENT; VIRILIZATION;

EID: 70349932628     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-0942     Document Type: Article

References (36)

1. Speiser PW, White PC 2003 Congenital adrenal hyperplasia. N Engl J Med 349:776-788
2. Hughes IA 1998 Congenital adrenal hyperplasia-a continuum of disorders. Lancet 352:752-754
3. Cutler Jr GB, Laue L 1990 Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. N Engl J Med 323:1806-1813
4. Laue L, Merke DP, Jones JV, Barnes KM, Hill S, Cutler Jr GB 1996 A preliminary study of flutamide, testolactone, and reduced hydrocortisone dose in the treatment of congenital adrenal hyperplasia. J Clin Endocrinol Metab 81:3535-3539 (Pubitemid 26339911)
5. Einaudi S, Lala R, Corrias A, Matarazzo P, Pagliardini S, de Sanctis C 1993 Auxological and biochemical parameters in assessing treatment of infants and toddlers with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Pediatr Endocrinol 6:173-178 (Pubitemid 23240293)
6. Bonfig W, Bechtold S, Schmidt H, Knorr D, Schwarz HP 2007 Reduced final height outcome in congenital adrenal hyperplasia under prednisone treatment: deceleration of growth velocity during puberty. J Clin Endocrinol Metab 92:1635-1639 (Pubitemid 46997164)
7. Krone N, Braun A, Roscher AA, Knorr D, Schwarz HP 2000 Predicting phenotype in steroid 21-hydroxylase deficiency? Comprehensive genotyping in 155 unrelated, well defined patients from southern Germany. J Clin Endocrinol Metab 85:1059-1065 (Pubitemid 32269350)
8. Prader A, Largo RH, Molinari L, Issler C 1989 Physical growth of Swiss children from birth to 20 years of age. First Zurich longitudinal study of growth and development. Helv Paediatr Acta Suppl 52:1-125
9. Cole TJ, Freeman JV, Preece MA 1995 Body mass index reference curves for the UK. Arch Dis Child 73:25-29
10. Greulich WW, Pyle SI 1959 Radiographic atlas of skeletal development of the hand and wrist. 2nd ed. Palo Alto, CA: Stanford University Press
11. Largo RH, Prader A 1983 Pubertal development in Swiss girls. Helv Paediatr Acta 38:229-243
12. Largo RH, Prader A 1983 Pubertal development in Swiss boys. Helv Paediatr Acta 38:211-228
13. Manoli I, Kanaka-Gantenbein Ch, Voutetakis A, Maniati-Christidi M, Dacou-Voutetakis C 2002 Early growth, pubertal development, body mass index and final height of patients with congenital adrenal hyperplasia: factors influencing the outcome. Clin Endocrinol (Oxf) 57:669-676 (Pubitemid 35316986)
14. Stikkelbroeck NM, Van't Hof-Grootenboer BA, Hermus AR, Otten BJ, Van't Hof MA 2003 Growth inhibition by glucocorticoid treatment in salt-wasting 21-hydroxylase deficiency: in early infancy and (pre)puberty. J Clin Endocrinol Metab 88:3525-3530
15. Kirkland RT, Keenan BS, Holcombe JH, Kirkland JL, Clayton GW 1978 The effect of therapy on mature height in congenital adrenal hyperplasia. J Clin Endocrinol Metab 47:1320-1324 (Pubitemid 9091295)
16. Muirhead S, Sellers EA, Guyda H 2002 Indicators of adult height outcome in classical 21-hydroxylase deficiency congenital adrenal hyperplasia. J Pediatr 141:247-252
17. Joint LWPES/ESPE CAH Working Group 2002 Consensus statement on 21-hydroxylase deficiency from The Lawson Wilkins Pediatric Endocrine Society and The European Society for Pediatric Endocrinology. J Clin Endocrinol Metab 87:4048-4053
18. Devesa J, Barros MG, Gondar M, Tresguerres JA, Arce V 1995 Regulation of hypothalamic somatostatin by glucocorticoids. J Steroid Biochem Mol Biol 53:277-282
19. Frisch H, Waldhauser F, Lebl J, Solyom J, Hargitai G, Kovacs J, Pribilincova Z, Krzisnik C, Battelino T, MEWPE-CAH Study Group 2002 Congenital adrenal hyperplasia: lessons from a multinational study. Horm Res 57(Suppl 2):95-101 (Pubitemid 34639009)
20. Van der Kamp HJ, Otten BJ, Buitenweg N, De Muinck Keizer-Schrama SM, Oostdijk W, Jansen M, Delemarre-de Waal HA, Vulsma T, Wit JM 2002 Longitudinal analysis of growth and puberty in 21-hydroxylase deficiency patients. Arch Dis Child 87:139-144 (Pubitemid 34828021)
21. Hargitai G, Sólyom J, Battelino T, Lebl J, Pribilincová Z, Hauspie R, Kovács J, Waldhauser F, Frisch H 2001 Growth patterns and final height in congenital adrenal hyperplasia due to classical 21-hydroxylase deficiency. Horm Res 55:161-171
22. Eugster EA, Dimeglio LA, Wright JC, Freidenberg GR, Seshadri R, Pescovitz OH 2001 Height outcome in congenital adrenal hyperplasia caused by 21-hydroxylase deficiency: a meta-analysis. J Pediatr 138: 26-32 (Pubitemid 32097137)
23. Balsamo A, Cicognani A, Baldazzi L, Barbaro M, Baronio F, Gennari M, Bal M, Cassio A, Kontaxaki K, Cacciari E 2003 CYP21 genotype, adult height, and pubertal development in 55 patients treated for 21-hydroxylase deficiency. J Clin Endocrinol Metab 88:5680-5688 (Pubitemid 38033035)
24. Pinto G, Tardy V, Trivin C, Thalassinos C, Lortat-Jacob S, Nihoul-Fékété C, Morel Y, Brauner R 2003 Follow-up of 68 children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency: relevance of genotype for management. J Clin Endocrinol Metab 88:2624-2633 (Pubitemid 36724435)
25. Klingensmith GJ, Garcia SC, Jones HW, Migeon CJ, Blizzard RM 1977 Glucocorticoid treatment of girls with congenital adrenal hyperplasia: effects on height, sexual maturation, and fertility. J Pediatr 90: 996-1004
26. Jääskeläinen J, Voutilainen R 1997 Growth of patients with 21-hydroxylase deficiency: an analysis of factors influencing adult height. Pediatr Res 41:30-33 (Pubitemid 27008632)
27. Duck SC 1980 Acceptable linear growth in congenital adrenal hyperplasia. J Pediatr 97:93-96 (Pubitemid 10033772)
28. Mulaikal RM, Migeon CJ, Rock JA 1987 Fertility rates in female patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. N Engl J Med 316:178-182 (Pubitemid 17052760)
29. Premawardhana LD, Hughes IA, Read GF, Scanlon MF 1997 Longer term outcome in females with congenital adrenal hyperplasia (CAH): the Cardiff experience. Clin Endocrinol (Oxf) 46:327-332
30. Cabrera MS, Vogiatzi MG, New MI 2001 Long-term outcome in adult males with classic congenital adrenal hyperplasia. J Clin Endocrinol Metab 86:3070-3078 (Pubitemid 32673467)
31. Urban MD, Lee PA, Migeon CJ 1978 Adult height and fertility in men with congenital virilizing adrenal hyperplasia. N Engl J Med 299:1392-1396 (Pubitemid 9092482)
32. Yu AC, Grant DB 1995 Adult height in women with early-treated congenital adrenal hyperplasia (21-hydroxylase type): relation to body mass index in earlier childhood. Acta Paediatr 84:899-903
33. Young MC, Ribeiro J, Hughes IA 1989 Growth and body proportions in congenital adrenal hyperplasia. Arch Dis Child 64:1554-1558 (Pubitemid 19266061)
34. DiMartino-Nardi J, Stoner E, O'Connell A, New MI 1986 The effect of treatment of final height in classical congenital adrenal hyperplasia (CAH). Acta Endocrinol Suppl (Copenh) 279:305-314 (Pubitemid 17170014)
35. New MI, Gertner JM, Speiser PW, Del Balzo P 1989 Growth and final height in classical and nonclassical 21-hydroxylase deficiency. J Endocrinol Invest 12(8 Suppl 3):91-95 (Pubitemid 19258815)
36. Hughes IA, Read GF 1982 Menarche and subsequent ovarian function in girls with congenital adrenal hyperplasia. Horm Res 16:100-106